AF
TEVA icon

Arrow Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Arrow Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$18K – 343
2017
Q3 		$18K Hold
1,000
– – ﹤0.01% 261
2017
Q2 		$33K Hold
1,000
– – 0.01% 236
2017
Q1 		$32K Buy
1,000
+400
+67% +$13.7K 0.01% 235
2016
Q4 		$22K Sell
600
-60
-9% -$2.4K 0.01% 253
2016
Q3 		$30K Hold
660
– – 0.01% 235
2016
Q2 		$33K Sell
660
-240
-27% -$12.8K 0.01% 232
2016
Q1 		$48K Hold
900
– – 0.01% 220
2015
Q4 		$59K Hold
900
– – 0.02% 204
2015
Q3 		$51K Hold
900
– – 0.01% 200
2015
Q2 		$53K Sell
900
-268
-23% -$16.5K 0.01% 203
2015
Q1 		$73K Buy
1,168
+68
+6% +$3.95K 0.02% 189
2014
Q4 		$64K Hold
1,100
– – 0.02% 191
2014
Q3 		$59K Hold
1,100
– – 0.02% 209
2014
Q2 		$57K Hold
1,100
– – 0.02% 216
2014
Q1 		$59K Hold
1,100
– – 0.02% 209
2013
Q4 		$44K Hold
1,100
– – 0.01% 207
2013
Q3 		$42K Hold
1,100
– – 0.01% 206
2013
Q2 		$43K Buy
+1,100
New +$42.8K 0.01% 192

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Arrow Financial's TEVA Position: Q4 2017 in Review

Arrow Financial sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 1,000 shares — an estimated $18K sold.

Arrow Financial first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $73K in Q1 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Arrow Financial reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Arrow Financial sold 1,000 Teva Pharmaceuticals shares in Q4 2017, an estimated $18K.
  • Arrow Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Arrow Financial's Teva Pharmaceuticals position peaked at $73K in Q1 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Arrow Financial's 13F filing for Q4 2017, filed 5 Feb 2018.